Sugi Predict

Sugi Predict / Compounds / SCHEMBL4472564

SCHEMBL4472564

SCHEMBL4472564

COc1cc(NS(=O)(=O)c2ccc(C#N)cc2)c2ncccc2c1

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.79
▸ KMT2A Q03164 5/20 0.79
▸ TDP1 Q9NUW8 5/20 0.79
▸ LMNA P02545 1/20 0.76
▸ TP53 P04637 1/20 0.76
▸ MAPT P10636 1/20 0.76
▸ HPGD P15428 1/20 0.76
▸ TSHR P16473 1/20 0.76
▸ CXCR2 P25025 1/20 0.76
▸ AGTR1 P30556 1/20 0.76
▸ SMN1; SMN2 Q16637 1/20 0.76
▸ NPSR1 Q6W5P4 1/20 0.76
▸ SLC40A1 Q9NP59 10/20 0.76
▸ POLB P06746 1/20 0.72
▸ GLO1 Q04760 4/20 0.68
▸ CKS1B P61024 3/20 0.68
▸ SKP2 Q13309 3/20 0.68
▸ NFKBIA P25963 2/20 0.58
▸ RELA Q04206 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633886 0.89 MEN1 (1.00) MEN1KMT2ATDP1LMNATP53
SCHEMBL1505430 0.86 KMT2A (1.00) MEN1KMT2ATDP1LMNATP53
SCHEMBL29575795 0.86 KMT2A (1.00) MEN1KMT2ATDP1LMNATP53
SCHEMBL7197593 0.86 SLC40A1 (1.00) MEN1KMT2ATDP1LMNATP53
SCHEMBL4489851 0.85 MEN1 (0.84) MEN1KMT2ATDP1LMNATP53
SCHEMBL22111633 0.85 MEN1 (0.84) MEN1KMT2ATDP1LMNATP53
SCHEMBL22076984 0.84 MEN1 (1.00) MEN1KMT2ATDP1LMNATP53
SCHEMBL30925511 0.81 GLO1 (1.00) MEN1KMT2ATDP1LMNAMAPT
SCHEMBL13486175 0.81 GLO1 (1.00) MEN1KMT2ATDP1LMNAMAPT
SCHEMBL17506537 0.81 CKS1B (1.00) MEN1KMT2ATDP1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885TDP1 83/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885TDP1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.